A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Public ClinicalTrials.gov record NCT01004224. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Study identification
- NCT ID
- NCT01004224
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 208 participants
Conditions and interventions
Conditions
Interventions
- BGJ398 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 10, 2009
- Primary completion
- Oct 7, 2018
- Completion
- Oct 7, 2018
- Last update posted
- Oct 3, 2019
2009 – 2018
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Duarte | California | 91010 3000 | — |
| Novartis Investigative Site | Los Angeles | California | 90033 | — |
| Novartis Investigative Site | Los Angeles | California | 90095 | — |
| University of Colorado Dept. of Anschutz Cancer (3) | Aurora | Colorado | 80045 | — |
| Novartis Investigative Site | New Haven | Connecticut | 06520 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02114 | — |
| Novartis Investigative Site | Detroit | Michigan | 48201 | — |
| Memorial Sloan Kettering Cancer Center Onc. Dept.. | New York | New York | 10021 | — |
| Novartis Investigative Site | New York | New York | 10029 | — |
| Novartis Investigative Site | Columbus | Ohio | 43221 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19104 | — |
| Thomas Jefferson University Hospital Onc Dept | Philadelphia | Pennsylvania | 19107-5098 | — |
| Novartis Investigative Site | Pittsburgh | Pennsylvania | 15232 | — |
| Novartis Investigative Site | Memphis | Tennessee | 38120 | — |
| Novartis Investigative Site | Nashville | Tennessee | 37203 | — |
| Novartis Investigative Site | Salt Lake City | Utah | 84103 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01004224, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 3, 2019 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01004224 live on ClinicalTrials.gov.